Loading…
Dr. Reddy's Laboratories Limited is projected to rise to $13.06 by 2027, a +10% move from its current price of $11.83. RDY is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $11.63 | $11.83 | $12.04 | +0.01% |
| Aug 2 | $11.54 | $11.83 | $12.13 | +0.01% |
| Aug 3 | $11.48 | $11.83 | $12.20 | +0.02% |
| Aug 4 | $11.43 | $11.83 | $12.25 | +0.02% |
| Aug 5 | $11.38 | $11.83 | $12.31 | +0.03% |
| Aug 6 | $11.34 | $11.83 | $12.35 | +0.04% |
| Aug 7 | $11.30 | $11.84 | $12.40 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.30 | $11.84 | $12.40 | +0.04% |
| Week 2 | $11.09 | $11.84 | $12.64 | +0.09% |
| Week 3 | $10.93 | $11.85 | $12.83 | +0.13% |
| Week 4 | $10.80 | $11.85 | $13.00 | +0.17% |
| Week 5 | $10.69 | $11.86 | $13.15 | +0.21% |
| Week 6 | $10.59 | $11.86 | $13.28 | +0.26% |
| Week 7 | $10.50 | $11.87 | $13.41 | +0.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company with a global footprint spanning North America, Europe, India, Russia, and international markets.
The company operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, and it also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, provides contract research services, and manufactures and sells active pharmaceutical ingredients and steroids.
The Others segment engages in developing therapies in oncology and inflammation, and research, development, and commercialization of differentiated formulations. Dr. Reddy's offers products across therapeutic categories including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, nephrology, vaccines, vitamins and minerals, and pain management.
It was incorporated in 1984 and is headquartered in Hyderabad, India.
Dr. Reddy's Laboratories Limited (RDY) is listed with a current price of $11.38 and a market capitalization of $9.48B. It is ranked 910 by market capitalization among peers.
The stock sits in the Healthcare category and presents a forecast that envisions upside over the longer term. The 2026 forecast shows an average price of $11.38, with further potential growth implied by higher years, culminating in a 2050 average price of $61.36. The outlook shifts to bullish territory from 2030 onward, with rising averages through the decades.
A major floor 25.1% below — a decisive break under it would weaken the trend.
The nearest floor, 3.8% below — buyers have tended to step in here.
The nearest ceiling, 30.0% above — a clean break opens room to run.
A major ceiling 42.5% above — clearing it would confirm fresh momentum.
Key RDY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RDY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.78 | Buy | $11.83 | Buy |
| MA 10 | $11.98 | Sell | $12.06 | Sell |
| MA 20 | $12.78 | Sell | $12.54 | Sell |
| MA 50 | $13.33 | Sell | $13.10 | Sell |
| MA 100 | $13.43 | Sell | $13.38 | Sell |
| MA 200 | $13.70 | Sell | $13.64 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.50 | Neutral |
| Stoch RSI (14) | 69.35 | Neutral |
| CCI (20) | -77.89 | Neutral |
| Williams %R (14) | -70.78 | Info |
| MACD (12,26,9) | -0.10 | Sell |
| ROC (12) | -7.87 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 29.22 | Neutral |
| TRIX (15) | -0.48 | Sell |
| Awesome (5,34) | -1.52 | Sell |
| Ultimate (7,14,28) | 29.02 | Buy |
| Momentum (10) | -0.87 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 11.71 | Buy |
| ADX (14) | 27.97 | Sell |
| ATR (14) | 0.21 | Info |
The 30-day technical picture is NEUTRAL, with RSI(14) at 20. The 50-day simple moving average (SMA50) is $13.50 and the 200-day simple moving average (SMA200) is $13.77.
Support is at $11.38 and resistance at $15.38, suggesting a tight trading band around current levels. The 30-day range runs from a low of $10.01 to a high of $12.94, and the stock shows an annualized volatility of 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.38 | $11.83 | $15.03 | 0% | Neutral | |
| $10.71 | $13.06 | $16.65 | +10% | Neutral | |
| $10.95 | $13.61 | $17.82 | +15% | Neutral | |
| $11.64 | $14.69 | $19.64 | +24% | Bullish | |
| $13.19 | $16.87 | $22.98 | +43% | Bullish | |
| $14.89 | $19.28 | $26.67 | +63% | Bullish | |
| $16.29 | $21.33 | $29.93 | +80% | Bullish | |
| $16.84 | $22.29 | $31.68 | +88% | Bullish | |
| $17.34 | $23.18 | $33.36 | +96% | Bullish | |
| $18.20 | $24.56 | $35.72 | +108% | Bullish | |
| $25.66 | $36.11 | $55.06 | +205% | Bullish | |
| $46.92 | $70.83 | $115.77 | +499% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $11.38 | $11.83 | $13.78 | +0.00% |
| August 2026 | $10.31 | $12.02 | $14.29 | +1.64% |
| September 2026 | $10.14 | $11.90 | $14.27 | -1.06% |
| October 2026 | $10.13 | $11.94 | $14.43 | +0.35% |
| November 2026 | $10.37 | $12.27 | $14.91 | +2.75% |
| December 2026 | $10.36 | $12.30 | $15.03 | +0.25% |
Click any year to see its month-by-month RDY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect RDY to range from $11.38 to $15.03 through 2026. The $11.83 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The RDY price prediction for 2027 points to an average of $13.06 (low $10.71, high $16.65) — a potential gain of +10% on today's $11.83. A consolidation phase looks the most probable path here.
In 2028, RDY is projected to trade between $10.95 and $17.82, averaging $13.61 — a potential gain of +15% from today's $11.83. That is up +4% on the projected 2027 average. Price action looks broadly range-bound.
Dr. Reddy's Laboratories Limited's 2029 outlook centres on $14.69, within a $11.64 to $19.64 range. That is up +8% on the projected 2028 average. That marks a +24% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, RDY could reach as high as $22.98, with a base case around $16.87 and support toward $13.19 — roughly +43% from $11.83. Momentum favours further upside here.
Expect RDY to range from $14.89 to $26.67 through 2031. The $19.28 average target implies a +63% move from current prices. That is up +14% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The RDY price prediction for 2032 points to an average of $21.33 (low $16.29, high $29.93) — a potential gain of +80% on today's $11.83. Momentum favours further upside here.
In 2033, RDY is projected to trade between $16.84 and $31.68, averaging $22.29 — a potential gain of +88% from today's $11.83. That is up +4% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Dr. Reddy's Laboratories Limited's 2034 outlook centres on $23.18, within a $17.34 to $33.36 range. That is up +4% on the projected 2033 average. That marks a +96% change versus current levels. Momentum favours further upside here.
By 2035, RDY could reach as high as $35.72, with a base case around $24.56 and support toward $18.20 — roughly +108% from $11.83. Buyers look set to stay in control over this stretch.
Expect RDY to range from $25.66 to $55.06 through 2040. The $36.11 average target implies a +205% move from current prices. That is up +47% on the projected 2035 average. Momentum favours further upside here.
The RDY price prediction for 2050 points to an average of $70.83 (low $46.92, high $115.77) — a potential gain of +499% on today's $11.83. Buyers look set to stay in control over this stretch.
Investing $1,000 in RDY today (≈ 84.530854 RDY) could be worth
$5,987.23
+$4,987.23 (+499%) by 2050 · US Dollar
Based on the average projected RDY price of $70.83 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RDYwould be worth at today's price.
$1,000 invested in RDY on Jul 30, 2025 (≈ 70.921984 RDY) would be worth
$839.01
-$160.99 (-16.1%) today · 0.84× · US Dollar
Based on a RDY entry price of $14.1 vs. today's $11.83.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.8 | $1,002.54 | +0.3% |
| 1 month ago | $14.49 | $816.43 | -18.4% |
| 3 months ago | $13.72 | $862.24 | -13.8% |
| 6 months ago | $13.42 | $881.52 | -11.8% |
| 1 year ago | $14.1 | $839.01 | -16.1% |
| All time (5.0y) ago | $12.52 | $944.59 | -5.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RDY forecast.
Our base-case forecast reaches $24.00 around 2035.
Implied market cap at $24.00: $19.99B
The multi-year forecast shows a clear uptrend and bullish sentiment from 2030 onward. In 2026, the min price is $11.38, the avg is $11.38, the max is $14.37, with an ROI of 0% and neutral sentiment. By 2030, the avg rises to $15.59 with an ROI of 37% and a bullish outlook; the range extends to a max of $21.36.
In 2040 the forecast calls for an avg of $32.17 and an ROI of 182.7%, with the max reaching $49.47. By 2050, the avg is $61.36 and the max $101.34, implying an ROI of 439.2% with bullish sentiment. These figures indicate substantial long-term upside, albeit as estimates rather than guarantees.
The trajectory reflects a persistent rise in expected value from 2030 through 2050 along with sustained bullish sentiment.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $15.59 with a bullish sentiment and an ROI of 37%. The min is $12.14 and the max is $21.36.
Forecasts show bullish sentiment from 2030 onward with rising averages and ROI peaking at 439.2% by 2050 (avg $61.36, max $101.34). Early years in the forecast are neutral, with 2026 showing an avg of $11.38 and ROI of 0%.
Yes. The 2050 max forecast is $101.34, and the 2040 max forecast is $49.47. Therefore, reaching $50 is within the model’s stated ranges by 2050, though 2040 would be just under the 50 level.
The 30-day range is $10.01 to $12.94.
RSI(14) is 20, and technical sentiment is NEUTRAL.
Dr. Reddy's Laboratories Limited Community Discussion
0Share your Dr. Reddy's Laboratories Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.